The Impact of Adherence to Disease-Modifying Therapies on Functional Outcomes in Veterans with Multiple Sclerosis
Background: Patients who adhere to their DMTs have lower rate of MS-related relapses and disability. Objective: We sought to determine the adherence rate to disease-modifying therapies (DMTs) and its impact on functional outcome(s) in veterans with multiple sclerosis (MS). Method: We reviewed the el...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-07-01
|
| Series: | Journal of Central Nervous System Disease |
| Online Access: | https://doi.org/10.1177/11795735211028769 |
| _version_ | 1818846691347922944 |
|---|---|
| author | Meheroz H Rabadi Kimberly Just Chao Xu |
| author_facet | Meheroz H Rabadi Kimberly Just Chao Xu |
| author_sort | Meheroz H Rabadi |
| collection | DOAJ |
| description | Background: Patients who adhere to their DMTs have lower rate of MS-related relapses and disability. Objective: We sought to determine the adherence rate to disease-modifying therapies (DMTs) and its impact on functional outcome(s) in veterans with multiple sclerosis (MS). Method: We reviewed the electronic records of 279 veterans with MS who were periodically followed in our MS clinic. We compared 3 groups of patients, defined according to their adherence to DMTs (non-adherent; poorly adherent; adherent) on their effect on disability progression and time to sustained EDSS score of 6. Results: There were 148 (53%) veterans with MS who were non-adherent to any DMT medication(s) while of the 131 (47%) veterans who were taking medications, 118 (42%) had a good- and 13 (5%) had poor-adherence. The mean age at MS onset was 36.6 (± 11.2) and mean duration of MS for the sample was 24 ± 13.5 years. The mean initial EDSS and TFIM scores were 4.09 ± 2.9 SD and 104 ± 25.7 for the study sample. The change in MMSE, TFIM scores, and time to sustained EDSS score of 6 significantly favored the good- compared to the non-adherence group ( P < .01). Conclusion: This study suggests that veterans with MS who adhered to their DMTs had less decline in their MS-related cognition, disease severity and disability compared to non- and poorly-adherent groups even after adjusting for age, gender, MS duration, and type. Time to EDSS score of 6 was significantly prolonged in the good-adherence group. |
| first_indexed | 2024-12-19T05:49:35Z |
| format | Article |
| id | doaj.art-2c0eb1870f4c40e6874062860556fc6d |
| institution | Directory Open Access Journal |
| issn | 1179-5735 |
| language | English |
| last_indexed | 2024-12-19T05:49:35Z |
| publishDate | 2021-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of Central Nervous System Disease |
| spelling | doaj.art-2c0eb1870f4c40e6874062860556fc6d2022-12-21T20:33:40ZengSAGE PublishingJournal of Central Nervous System Disease1179-57352021-07-011310.1177/11795735211028769The Impact of Adherence to Disease-Modifying Therapies on Functional Outcomes in Veterans with Multiple SclerosisMeheroz H Rabadi0Kimberly Just1Chao Xu2Department of Neurology, The Oklahoma University Health Sciences Center, Oklahoma, UKOklahoma City Veterans Affairs Medical Center, Oklahoma, UKDepartment of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center (Statistician), Oklahoma, UKBackground: Patients who adhere to their DMTs have lower rate of MS-related relapses and disability. Objective: We sought to determine the adherence rate to disease-modifying therapies (DMTs) and its impact on functional outcome(s) in veterans with multiple sclerosis (MS). Method: We reviewed the electronic records of 279 veterans with MS who were periodically followed in our MS clinic. We compared 3 groups of patients, defined according to their adherence to DMTs (non-adherent; poorly adherent; adherent) on their effect on disability progression and time to sustained EDSS score of 6. Results: There were 148 (53%) veterans with MS who were non-adherent to any DMT medication(s) while of the 131 (47%) veterans who were taking medications, 118 (42%) had a good- and 13 (5%) had poor-adherence. The mean age at MS onset was 36.6 (± 11.2) and mean duration of MS for the sample was 24 ± 13.5 years. The mean initial EDSS and TFIM scores were 4.09 ± 2.9 SD and 104 ± 25.7 for the study sample. The change in MMSE, TFIM scores, and time to sustained EDSS score of 6 significantly favored the good- compared to the non-adherence group ( P < .01). Conclusion: This study suggests that veterans with MS who adhered to their DMTs had less decline in their MS-related cognition, disease severity and disability compared to non- and poorly-adherent groups even after adjusting for age, gender, MS duration, and type. Time to EDSS score of 6 was significantly prolonged in the good-adherence group.https://doi.org/10.1177/11795735211028769 |
| spellingShingle | Meheroz H Rabadi Kimberly Just Chao Xu The Impact of Adherence to Disease-Modifying Therapies on Functional Outcomes in Veterans with Multiple Sclerosis Journal of Central Nervous System Disease |
| title | The Impact of Adherence to Disease-Modifying Therapies on Functional Outcomes in Veterans with Multiple Sclerosis |
| title_full | The Impact of Adherence to Disease-Modifying Therapies on Functional Outcomes in Veterans with Multiple Sclerosis |
| title_fullStr | The Impact of Adherence to Disease-Modifying Therapies on Functional Outcomes in Veterans with Multiple Sclerosis |
| title_full_unstemmed | The Impact of Adherence to Disease-Modifying Therapies on Functional Outcomes in Veterans with Multiple Sclerosis |
| title_short | The Impact of Adherence to Disease-Modifying Therapies on Functional Outcomes in Veterans with Multiple Sclerosis |
| title_sort | impact of adherence to disease modifying therapies on functional outcomes in veterans with multiple sclerosis |
| url | https://doi.org/10.1177/11795735211028769 |
| work_keys_str_mv | AT meherozhrabadi theimpactofadherencetodiseasemodifyingtherapiesonfunctionaloutcomesinveteranswithmultiplesclerosis AT kimberlyjust theimpactofadherencetodiseasemodifyingtherapiesonfunctionaloutcomesinveteranswithmultiplesclerosis AT chaoxu theimpactofadherencetodiseasemodifyingtherapiesonfunctionaloutcomesinveteranswithmultiplesclerosis AT meherozhrabadi impactofadherencetodiseasemodifyingtherapiesonfunctionaloutcomesinveteranswithmultiplesclerosis AT kimberlyjust impactofadherencetodiseasemodifyingtherapiesonfunctionaloutcomesinveteranswithmultiplesclerosis AT chaoxu impactofadherencetodiseasemodifyingtherapiesonfunctionaloutcomesinveteranswithmultiplesclerosis |